Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
NCT06196008
Recruiting
This clinical trial compares telephone-based physical activity coaching to self monitored physical activity for improving physical function in older adults who are undergoing surgery for lung cancer and their caregivers. Lung cancer surgery in older adults is associated with functional declines and unique challenges. Performing physical activity around the time of surgery has been shown to improve functional outcomes in patients and exercise programs delivered via telehealth may improve access a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Yale New Haven Medical Center, New Haven, Connecticut
Conditions: Lung Carcinoma
Register for Updates
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
NCT05612594
Recruiting
The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug). The main question it aims to answer is: * If SGLT2i will reduce anatomic and physiologic traits, clinical measures of OSA and sleep deficiency in participants * If improvement in clinical measures are because of improvement in the anatom... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Yale New Haven Health, New Haven, Connecticut
Conditions: Sleep Apnea
Register for Updates
Regulating Blood Pressure During Recovery from Intracerebral Hemorrhage and Ischemic Stroke
NCT04760717
Recruiting
The purpose of this research study is to determine whether blood pressure treatment regimens with spironolactone are better than blood pressure treatment regimens without spironolactone at lowering blood pressure in stroke survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Intracerebral Hemorrhage, Spironolactone, Ischemic Stroke
Register for Updates
CLOZAPINE Response in Biotype-1
NCT04580134
Recruiting
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/27/2024
Locations: Hartford Healthcare, Hartford, Connecticut
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Register for Updates
Post Market Registry Study of the Philips QuickClear Mechanical Thrombectomy System
NCT05928221
Recruiting
A post-market study of the QuickClear Mechanical Thrombectomy system used for the removal of acute Deep Vein Thrombosis (DVT) from the deep veins of legs in the setting of an office interventional suite.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
08/23/2024
Locations: Vascular Care Connecticut, Darien, Connecticut
Conditions: Acute Deep Venous Thrombosis of Ileofemoral Vein
Register for Updates
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/21/2024
Locations: Connecticut Children's Hospital, Hartford, Connecticut
Conditions: Neuroblastoma
Register for Updates
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
NCT06385236
Recruiting
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change trea... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/16/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Moderate to Severe Asthma
Register for Updates
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
NCT02491099
Recruiting
Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progression-free for at least 6 months after initiating therapy. Secondary Objectives: To assess objective response rate and durable disease control rate. To assess overall survival. To assess the safety profile of Afatinib in uterine serous carcinoma patients.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/16/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: HER2/Neu+ Uterine Serous Carcinoma
Register for Updates
Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records
NCT04569903
Recruiting
The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Transthyretin Amyloidosis
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates